← All trials
NCT05079789
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 8, 2020
- Primary completion
- Jun 8, 2023
- Completion date
- Jun 30, 2023
- First posted
- Oct 15, 2021
- Last posted
- Oct 15, 2021
- Enrollment
- 36
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of TuebingenLead sponsor
- University of TuebingenReponsible party - principal investigator
- University of TuebingenOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.